MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.…
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics (NASDAQ: MPLT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 133 employees.
The shares were at 5.940 USD on 20 November 2026, down 59.3% over 52 weeks. Its 52-week range is 5.930 USD to 40.43 USD, and it trades at the bottom of that range.
Its market capitalisation is 330.12M USD.
MapLight Therapeutics reports return on equity of -35.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 282.39M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.